MedPath

Finnish Venous Ulcer Study (FINNULCER Study)

Not Applicable
Recruiting
Conditions
Venous Leg Ulcer
Interventions
Procedure: Endothermal Ablation
Procedure: Foam Sclerotherapy
Registration Number
NCT04737941
Lead Sponsor
Oulu University Hospital
Brief Summary

This multicenter randomized controlled trial evaluates the effect of first-visit foam sclerotherapy (including sub-ulcer foam sclerotherapy) in patients with venous leg ulcer.

Detailed Description

To evaluate the effect of first-visit foam sclerotherapy, patients with venous leg ulcers are randomly assigned to either the first-visit foam sclerotherapy group or the scheduled treatment group. The scheduled treatment group represents the current standard of care. The primary outcome of this study is the time to ulcer healing.

In addition to the first-visit treatment in the study group, both groups receive endothermal ablation and/or foam sclerotherapy to (further) treat ulcer-related insufficient veins and truncal insufficiency in scheduled treatment visit(s).

Class 2 thigh-high compression or the best possible compression therapy tolerated by the patient is provided in both groups. The follow-up period for the primary outcome is one year.

For this study, based on Oulu University Hospital's retrospective data (partly published in Pihlaja et al 2020) of venous ulcer healing the investigators assumed Hazard Ratio 1.5 for venous ulcer to heal in first-visit foam sclerotherapy group compared to scheduled treatment group.

Assuming drop-out of 10% this study recruits total of 248 patients (a=0.05, b=0.2).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
248
Inclusion Criteria
  • Patient informed consent
  • Venous ulcer, aged from one month to one year
  • Duplex ultrasonography verified (vein reflux greater than >0.5 second) superficial venous insufficiency
  • Sufficient arterial circulation (at least on criterion met: Palpable distal pulses / ankle-brachial index > 0,8 / Toe pressure >60mmhg)
Exclusion Criteria
  • Leg ulcers other than venous etiology
  • Ulcers requiring operation theater revision
  • Patent foramen ovale
  • Several times recurrent (over 3 recurrences) venous ulcer
  • Body Mass Index over 40
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Scheduled treatmentFoam SclerotherapyScheduled treatment group patients are treated with scheduled endovenous ablation including foam sclerotherapy and/or endothermal ablation depending on reflux anatomy. Compression therapy is started immediately.
Scheduled treatmentEndothermal AblationScheduled treatment group patients are treated with scheduled endovenous ablation including foam sclerotherapy and/or endothermal ablation depending on reflux anatomy. Compression therapy is started immediately.
Immediate foam sclerotherapyFoam SclerotherapyImmediate foam sclerotherapy group patients are treated with immediate (first-visit) foam sclerotherapy and truncal vein endothermal ablation is scheduled when anatomy is suitable. Compression therapy is started immediately.
Immediate foam sclerotherapyEndothermal AblationImmediate foam sclerotherapy group patients are treated with immediate (first-visit) foam sclerotherapy and truncal vein endothermal ablation is scheduled when anatomy is suitable. Compression therapy is started immediately.
Primary Outcome Measures
NameTimeMethod
Time to ulcer Healing0-365 days

Complete re-epithelialisation of ulcer area

Secondary Outcome Measures
NameTimeMethod
EQ-5D Questionnaire0-365 days

Score 0-100 where higher is better

Venous ulcer area0-365 days

Reduction on venous ulcer maximum diameter

Wound-QOL Questionnaire0-365 days

Score 0-17 where lower is better

Trial Locations

Locations (5)

Oulu University Hospital

🇫🇮

Oulu, Finland

Turku University Hospital

🇫🇮

Turku, Finland

Keski-Suomen keskussairaala

🇫🇮

Jyväskylä, Finland

Helsinki University Central Hospital

🇫🇮

Helsinki, Finland

Vaasa Central Hospital

🇫🇮

Vaasa, Finland

© Copyright 2025. All Rights Reserved by MedPath